The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Enspryng to be approved to treat neuromyelitis optica spectrum disorder in people aged 12 years and older, according to a Roche press release.
The recommendation for Enspryng (satralizumab) is for the treatment of patients with anti-aquaporin-4 antibody neuromyelitis optica spectrum disorder (NMOSD) as a monotherapy or in concert with immunosuppressive therapy, the release said.
The treatment, a humanized monoclonal antibody that targets interleukin-6 receptor activity, is administered